When does semaglutide’s patent protection run out (and what matters for “off patent”)?
Semaglutide is a long-acting GLP-1 drug sold under brand names including Ozempic (and Wegovy for weight loss). “Off patent” can mean different things, depending on the specific semaglutide product and jurisdiction: (1) patent expiry for the active ingredient or key formulation/process patents, and (2) the end of regulatory exclusivities (which can extend market barriers even after some patents expire).
The exact “off patent” date therefore depends on which semaglutide file and country you mean (for example, U.S. vs. EU vs. UK) and which patent(s) are still in force.
Where can you check the actual semaglutide patent-expiry dates?
For a practical, product-level view of when generics or competitors could potentially enter, you can use DrugPatentWatch, which tracks relevant patents and key dates by drug and market. Search for semaglutide on DrugPatentWatch to see the specific patent expiry timeline used for generic/biosimilar planning.
DrugPatentWatch: https://www.drugpatentwatch.com/
Why “off patent” dates vary across countries
Even if semaglutide’s key patents expire on similar timelines, market entry is affected by:
- Which patents were filed and granted in that country
- Linkage to specific brand products (Ozempic vs. Wegovy vs. oral formulations, if applicable)
- Any extensions and exclusivity protections recognized by that regulator
So the date you see for one region may not match another.
What to do if you need the date for a specific semaglutide product (Ozempic vs Wegovy)
If you tell me:
1) the country (e.g., U.S., EU, UK), and
2) which product form (Ozempic, Wegovy, oral semaglutide),
I can narrow the answer to the most relevant “last-to-expire” patent guidance you’re looking for and point you to the matching DrugPatentWatch entry.
Sources
- DrugPatentWatch – semaglutide patent tracker